Rezultati pretraživanja
  1. 8. pro 2009.

    BIG congrats to California Stem Cell for receiving from today for SMA stem cell therapy! http://bit.ly/6F1rgh

  2. 6. sij

    receives first regulatory designation for PRGN-3006 UltraCAR-T

  3. 9. lis 2017.

    Juno's BCMA-targeted CAR T has received for multiple myeloma from FDA. Impt. info:

  4. 30. ruj 2014.
  5. 11. srp 2018.

    Are you planning to apply for an ? Please be aware that the new portal will be mandatory for processes (application & post-designation activities) as of 19 September 2018 🕒🆕 +info & guidelines:

  6. 15. kol 2017.

    The plans to alleviate an backlog. How will this impact your R&D intensive company?

  7. 19. stu 2018.

    The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to lead product candidate A4250, an ileal bile acid transporter (IBAT) inhibitor, for the treatment of Alagille syndrome.

  8. 8. lip 2015.

    MN-166 from MediciNova receives FDA for :

  9. 4. kol 2015.

    Receives from the European Commission for SGX301 as a Treatment for

  10. The has granted to for the treatment of patients with

  11. 11. sij 2018.

    : Helsinn & MEI Pharma announce that received from for acute . Find out more

  12. 12. ruj 2019.

    A big shout-out goes to RDL customer on their recent !!!

  13. 15. lip 2016.

    Relmada's d-Methadone receives | Drug Target Review

  14. 3. stu 2016.

    grants in the EU to Philogen's L19 TNF fusion protein for use in Soft Tissue Sarcoma

  15. 7. pro 2016.

    grants for a disorder with no approved treatment

  16. 3. lis 2019.
  17. 25. sij 2017.

    A new potential treatment receives , see more going on this week!

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.